New study aims to help breast cancer patients stick with Life-Saving hormone therapy
NCT ID NCT07071038
First seen Feb 12, 2026 · Last updated May 10, 2026 · Updated 14 times
Summary
This study looks at two ways to manage side effects from aromatase inhibitors, a hormone therapy for early-stage breast cancer. About half of women stop taking these drugs early due to side effects, raising the risk of cancer returning. The study will compare switching to a different aromatase inhibitor versus using guideline-recommended care to relieve symptoms, with the goal of helping 62 women complete their full 5-year treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dartmouth Cancer Center
RECRUITINGLebanon, New Hampshire, 03756, United States
Contact
Conditions
Explore the condition pages connected to this study.